Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations

ir@sedanamedical.com Send Email

The Share

See More

Press Releases

Report from Sedana Medical’s annual general meeting on 22 May 2024

Regulatory

Sedana Medical AB (publ)’s annual general meeting was held on Wednesday, 22 May 2024 and the main re…

Sedana Medical AB's Interim report January-March 2024

Regulatory

Off to a strong start with record sales in Q1

Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US

Non-regulatory

Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSP…

View All Press Releases

Financial Calendar

Annual General Meeting 22 May 2024 14:00
Interim Report Q2 2024 23 July 2024 07:00

See More